BSE Live
Apr 16, 16:01Prev. Close
55.17
Open Price
64.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Balance Sheet of OXYGENTA PHARMACEUTICAL (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | |
| Total Share Capital | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | |
| Reserves and Surplus | -51.15 | -45.36 | -42.11 | -37.58 | -31.77 | |
| Total Reserves and Surplus | -51.15 | -45.36 | -42.11 | -37.58 | -31.77 | |
| Total Shareholders Funds | -40.95 | -35.16 | -31.91 | -27.38 | -21.57 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 25.44 | 20.87 | 18.02 | 18.49 | 16.65 | |
| Deferred Tax Liabilities [Net] | 1.13 | 1.28 | 0.00 | 0.00 | 1.38 | |
| Other Long Term Liabilities | 17.16 | 17.44 | 11.19 | 10.72 | 2.55 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 43.72 | 39.59 | 29.21 | 29.21 | 20.59 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.50 | 0.49 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 8.10 | 8.95 | 10.76 | 9.26 | 15.14 | |
| Other Current Liabilities | 7.25 | 7.28 | 7.90 | 7.32 | 5.14 | |
| Short Term Provisions | 0.00 | 0.00 | 1.00 | 0.66 | 0.47 | |
| Total Current Liabilities | 15.85 | 16.73 | 19.66 | 17.24 | 20.75 | |
| Total Capital And Liabilities | 18.62 | 21.16 | 16.96 | 19.07 | 19.77 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 11.42 | 11.90 | 12.29 | 12.45 | 12.80 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.06 | 0.43 | 0.07 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 11.42 | 11.90 | 12.35 | 12.88 | 12.87 | |
| Non-Current Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.37 | 0.36 | 0.28 | 0.27 | 1.43 | |
| Other Non-Current Assets | 0.01 | 0.04 | 0.04 | 0.04 | 0.00 | |
| Total Non-Current Assets | 11.85 | 12.35 | 12.72 | 13.24 | 14.35 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 4.25 | 5.33 | 1.56 | 1.88 | 0.93 | |
| Trade Receivables | 0.42 | 0.51 | 0.48 | 0.86 | 1.48 | |
| Cash And Cash Equivalents | 0.12 | 0.02 | 0.01 | 0.02 | 0.01 | |
| Short Term Loans And Advances | 0.48 | 1.09 | 0.56 | 0.46 | 1.51 | |
| OtherCurrentAssets | 1.50 | 1.85 | 1.63 | 2.60 | 1.48 | |
| Total Current Assets | 6.77 | 8.80 | 4.24 | 5.83 | 5.42 | |
| Total Assets | 18.62 | 21.16 | 16.96 | 19.07 | 19.77 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1.20 | 1.20 | 1.20 | 1.95 | 1.62 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | -- | 0.05 | 0.05 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
09.02.2026
OXYGENTA PHARMA Standalone December 2025 Net Sales at Rs 33.93 crore, up 2.18% Y-o-Y
12.11.2025
OXYGENTA PHARMA Standalone September 2025 Net Sales at Rs 14.30 crore, up 2.12% Y-o-Y
11.06.2025
OXYGENTA PHARMA Standalone March 2025 Net Sales at Rs 49.47 crore, up 368.77% Y-o-Y
25.11.2024
OXYGENTA PHARMA Standalone September 2024 Net Sales at Rs 14.01 crore, up 7.11% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth